Roth Capital Reiterates Buy On Stemline Therapeutics, $62 PT
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics Inc (NASDAQ:STML) with a price target of $62.00.
Pantginis noted, “STML initiated a new trial of SL-401 in AML patients who have achieved CR following chemotherapy, but who are at high risk for relapse due to minimal residual disease in the bone marrow. SL-401 is targeted to AML cancer stem cells, which are thought to contribute to minimal residual disease and eventual relapse. The company also has trials underway for SL-401 in BPDCN and r/r AML and for SL-701 in GBM.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -14.2% and a 28.6% success rate. Pantginis has a -23.5% average return when recommending STML, and is ranked #3329 out of 3335 analysts.